Thomas Schluep
Geen lopende functies
Profiel
Dr. Thomas Schluep is Chief Scientific Officer at Calando Pharmaceuticals, Inc. and Vice President-Program Management at Arrowhead Research Corp.
Dr. Schluep was previously employed as Chief Scientific Officer by Insert Therapeutics, Inc., a Principal by Canji, Inc., and a Principal by Massachusetts Institute of Technology.
He received his graduate degree from the Swiss Federal Institute of Technology and a doctorate degree from the Swiss Federal Institute of Technology.
Eerdere bekende functies van Thomas Schluep
Bedrijven | Functie | Einde |
---|---|---|
Insert Therapeutics, Inc.
Insert Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Insert Therapeutics, Inc. researches and develops therapeutic products. It is using nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company was founded in February 2000 by Mark Davis and is located in Pasadena, CA | Chief Tech/Sci/R&D Officer | 08-09-2008 |
ARROWHEAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Canji, Inc.
Canji, Inc. Medical/Nursing ServicesHealth Services Part of Merck & Co., Inc., Canji, Inc. is a gene therapy research company. The private company is based in San Diego, CA. Canji was acquired by Schering-Plough Corp., part of Merck & Co., Inc. from November 03, 2009 on February 02, 1996 for $54.50 million. | Corporate Officer/Principal | - |
Calando Pharmaceuticals, Inc.
Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calando Pharmaceuticals, Inc. engages in the design and development of drug-delivery-enhanced small molecule therapeutics. The company was established in 2000 and is headquartered in Pasadena, CA. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Thomas Schluep
Swiss Federal Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Calando Pharmaceuticals, Inc.
Calando Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Calando Pharmaceuticals, Inc. engages in the design and development of drug-delivery-enhanced small molecule therapeutics. The company was established in 2000 and is headquartered in Pasadena, CA. | Health Technology |
Canji, Inc.
Canji, Inc. Medical/Nursing ServicesHealth Services Part of Merck & Co., Inc., Canji, Inc. is a gene therapy research company. The private company is based in San Diego, CA. Canji was acquired by Schering-Plough Corp., part of Merck & Co., Inc. from November 03, 2009 on February 02, 1996 for $54.50 million. | Health Services |
Insert Therapeutics, Inc.
Insert Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Insert Therapeutics, Inc. researches and develops therapeutic products. It is using nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company was founded in February 2000 by Mark Davis and is located in Pasadena, CA | Commercial Services |